XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25
On March 25, 2025, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the fourth quarter and full year 2024 and provided a business...
198 Views
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine
On January 13, 2025, X4 Pharmaceuticals, Inc. (XFOR) announced a licensing agreement with Norgine to commercialize mavorixafor in Europe,...
291 Views
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia
On November 13, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the third quarter of 2024 and provided a business...
167 Views
XFOR: First Commercial Sales of XOLREMDI
On August 8, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the second quarter of 2024 and provided a business...
206 Views
XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients
On June 27, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced positive interim results from the company's ongoing Phase 2 trial of mavorixafor in...
178 Views